Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients
| Autor: | B. Dautzenberg, D. Sassella, D Vittecoq, P Castellani, C Truffot-Pernot, N. Pirotta, J L Pellegrin |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Rifabutin medicine.drug_class medicine.medical_treatment AIDS-Related Opportunistic Infections Mycobacterium avium-intracellulare infection Antibiotics Administration Oral Bacteremia Placebo Gastroenterology Placebos Double-Blind Method Internal medicine medicine Humans Pharmacology (medical) Mycobacterium avium-intracellulare Infection Antibacterial agent Pharmacology Acquired Immunodeficiency Syndrome Chemotherapy business.industry Middle Aged Mycobacterium avium Complex bacterial infections and mycoses medicine.disease Anti-Bacterial Agents Infectious Diseases Immunology Female business Research Article medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 40:1722-1725 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | Rifabutin, 600 mg/day, was compared with a placebo in the early treatment of culture-proven Mycobacterium avium bacteremia in patients with AIDS. Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in the number of CFU of M. avium organisms per milliliter of blood by a factor of > or = 0.5 log from the baseline, was observed in 7 of 10 (70%) evaluable rifabutin patients and in 1 of 13 (8%) evaluable placebo patients (P = 0.002). Rifabutin is active against M. avium as a single agent and can make a significant contribution to combination regimens for the treatment of disseminated M. avium infection in AIDS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|